Wake Forest Technology
The Wake Forest Technology Development Program is a collaborative initiative established by Wake Forest Baptist Medical Center and Pappas Capital to encourage and expand the development of new research discoveries and inventions at the Center into innovative new medical products. The initiative focuses on the bottleneck that academic research centers and their faculty face in advancing their high-potential but early-stage and therefore high-risk ideas and inventions to the point where they can attract and reward private sector investment. The program illustrates Pappas Capital’s innovative strategic approach to this challenging phase of emerging technology development: Connect leading academic research centers to the firm’s experience, expertise, and network to leverage the flow of transformative new medical products from their translational pipeline.
February 1, 2017 – Chondrial Therapeutics secures up to $22.6 million in Series A financing and licenses novel technology for the treatment of Friedreich’s Ataxia
January 11, 2017 – Pappas Capital and Wake Forest Innovations Announce First Investments by the Catalyst Fund
October 7, 2015 – Wake Forest Baptist Medical Center Creates $15 Million Program to Develop Life Science Technologies